Global HIV Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global HIV Vaccine market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is caused by the human immunodeficiency virus (HIV), also known as the AIDS virus. HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc. At present, AIDS has become an important public health issue that seriously threatens the health of people around the world. In 1981, doctors discovered the first known case of HIV in the United States, and since then, more than 40 million people have died from the virus. According to data from the United Nations AIDS Program, men who have sex with men, female sex workers and their clients, transgender people, and people who inject drugs are at high risk. The virus is transmitted through the exchange of body fluids of infected people, such as blood, semen, and vaginal excrement. The most common is during unprotected sex, pregnancy and childbirth, transfusion of contaminated blood, or sharing of hypodermic needles. The human body cannot completely eliminate HIV. Therefore, once infected with the virus, an individual will remain HIV positive for life. However, through antiretroviral therapy (ART) drug treatment, HIV can be controlled, its progression can be significantly slowed, and gradually become a 'chronic disease'. In theory, before the emergence of curative drugs, AIDS patients need to take medication for life. Although there are relatively many existing antiviral therapies, they all have a clear disadvantage: long taking cycles and short intervals. Once the medication is stopped or missed, it will lead to the deterioration of AIDS; and long-term medication may also cause problems such as drug resistance and liver damage. Historically, vaccines have been the most effective means of preventing or even eradicating infectious diseases. They can safely and cost-effectively prevent disease, disability and death. HIV vaccine is a potential vaccine that can be both a preventive vaccine and a therapeutic vaccine, meaning that it can protect individuals from HIV infection and treat HIV-infected people. In theory, it can have a significant impact on transmission rates and help control epidemics.
This report is a detailed and comprehensive analysis for global HIV Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global HIV Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (Million Person), and average selling prices (US$/Person), 2021-2032
Global HIV Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Million Person), and average selling prices (US$/Person), 2021-2032
Global HIV Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Million Person), and average selling prices (US$/Person), 2021-2032
Global HIV Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (Million Person), and ASP (US$/Person), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for HIV Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global HIV Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
HIV Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe HIV Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of HIV Vaccine, with price, sales quantity, revenue, and global market share of HIV Vaccine from 2021 to 2026.
Chapter 3, the HIV Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the HIV Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and HIV Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of HIV Vaccine.
Chapter 14 and 15, to describe HIV Vaccine sales channel, distributors, customers, research findings and conclusion.
AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is caused by the human immunodeficiency virus (HIV), also known as the AIDS virus. HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc. At present, AIDS has become an important public health issue that seriously threatens the health of people around the world. In 1981, doctors discovered the first known case of HIV in the United States, and since then, more than 40 million people have died from the virus. According to data from the United Nations AIDS Program, men who have sex with men, female sex workers and their clients, transgender people, and people who inject drugs are at high risk. The virus is transmitted through the exchange of body fluids of infected people, such as blood, semen, and vaginal excrement. The most common is during unprotected sex, pregnancy and childbirth, transfusion of contaminated blood, or sharing of hypodermic needles. The human body cannot completely eliminate HIV. Therefore, once infected with the virus, an individual will remain HIV positive for life. However, through antiretroviral therapy (ART) drug treatment, HIV can be controlled, its progression can be significantly slowed, and gradually become a 'chronic disease'. In theory, before the emergence of curative drugs, AIDS patients need to take medication for life. Although there are relatively many existing antiviral therapies, they all have a clear disadvantage: long taking cycles and short intervals. Once the medication is stopped or missed, it will lead to the deterioration of AIDS; and long-term medication may also cause problems such as drug resistance and liver damage. Historically, vaccines have been the most effective means of preventing or even eradicating infectious diseases. They can safely and cost-effectively prevent disease, disability and death. HIV vaccine is a potential vaccine that can be both a preventive vaccine and a therapeutic vaccine, meaning that it can protect individuals from HIV infection and treat HIV-infected people. In theory, it can have a significant impact on transmission rates and help control epidemics.
This report is a detailed and comprehensive analysis for global HIV Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global HIV Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (Million Person), and average selling prices (US$/Person), 2021-2032
Global HIV Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Million Person), and average selling prices (US$/Person), 2021-2032
Global HIV Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Million Person), and average selling prices (US$/Person), 2021-2032
Global HIV Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (Million Person), and ASP (US$/Person), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for HIV Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global HIV Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
HIV Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Viral Vector Vaccines
- Recombinant Protein Vaccines
- Nucleic Acid Vaccines (including mRNA Vaccines)
- Other Vaccines
- Preventive Vaccine
- Therapeutic Vaccine
- Johnson and Johnson (Janssen)
- Sanofi-Pasteur
- Uvax Bio
- AELIX Therapeutics
- IAVI
- HKUMed
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe HIV Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of HIV Vaccine, with price, sales quantity, revenue, and global market share of HIV Vaccine from 2021 to 2026.
Chapter 3, the HIV Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the HIV Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and HIV Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of HIV Vaccine.
Chapter 14 and 15, to describe HIV Vaccine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global HIV Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Viral Vector Vaccines
1.3.3 Recombinant Protein Vaccines
1.3.4 Nucleic Acid Vaccines (including mRNA Vaccines)
1.3.5 Other Vaccines
1.4 Market Analysis by Application
1.4.1 Overview: Global HIV Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Preventive Vaccine
1.4.3 Therapeutic Vaccine
1.5 Global HIV Vaccine Market Size & Forecast
1.5.1 Global HIV Vaccine Consumption Value (2021 & 2025 & 2032)
1.5.2 Global HIV Vaccine Sales Quantity (2021-2032)
1.5.3 Global HIV Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Johnson and Johnson (Janssen)
2.1.1 Johnson and Johnson (Janssen) Details
2.1.2 Johnson and Johnson (Janssen) Major Business
2.1.3 Johnson and Johnson (Janssen) HIV Vaccine Product and Services
2.1.4 Johnson and Johnson (Janssen) HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Johnson and Johnson (Janssen) Recent Developments/Updates
2.2 Sanofi-Pasteur
2.2.1 Sanofi-Pasteur Details
2.2.2 Sanofi-Pasteur Major Business
2.2.3 Sanofi-Pasteur HIV Vaccine Product and Services
2.2.4 Sanofi-Pasteur HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Sanofi-Pasteur Recent Developments/Updates
2.3 Uvax Bio
2.3.1 Uvax Bio Details
2.3.2 Uvax Bio Major Business
2.3.3 Uvax Bio HIV Vaccine Product and Services
2.3.4 Uvax Bio HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Uvax Bio Recent Developments/Updates
2.4 AELIX Therapeutics
2.4.1 AELIX Therapeutics Details
2.4.2 AELIX Therapeutics Major Business
2.4.3 AELIX Therapeutics HIV Vaccine Product and Services
2.4.4 AELIX Therapeutics HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AELIX Therapeutics Recent Developments/Updates
2.5 IAVI
2.5.1 IAVI Details
2.5.2 IAVI Major Business
2.5.3 IAVI HIV Vaccine Product and Services
2.5.4 IAVI HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 IAVI Recent Developments/Updates
2.6 HKUMed
2.6.1 HKUMed Details
2.6.2 HKUMed Major Business
2.6.3 HKUMed HIV Vaccine Product and Services
2.6.4 HKUMed HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 HKUMed Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HIV VACCINE BY MANUFACTURER
3.1 Global HIV Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global HIV Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global HIV Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of HIV Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 HIV Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 HIV Vaccine Manufacturer Market Share in 2025
3.5 HIV Vaccine Market: Overall Company Footprint Analysis
3.5.1 HIV Vaccine Market: Region Footprint
3.5.2 HIV Vaccine Market: Company Product Type Footprint
3.5.3 HIV Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global HIV Vaccine Market Size by Region
4.1.1 Global HIV Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global HIV Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global HIV Vaccine Average Price by Region (2021-2032)
4.2 North America HIV Vaccine Consumption Value (2021-2032)
4.3 Europe HIV Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific HIV Vaccine Consumption Value (2021-2032)
4.5 South America HIV Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa HIV Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global HIV Vaccine Sales Quantity by Type (2021-2032)
5.2 Global HIV Vaccine Consumption Value by Type (2021-2032)
5.3 Global HIV Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global HIV Vaccine Sales Quantity by Application (2021-2032)
6.2 Global HIV Vaccine Consumption Value by Application (2021-2032)
6.3 Global HIV Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America HIV Vaccine Sales Quantity by Type (2021-2032)
7.2 North America HIV Vaccine Sales Quantity by Application (2021-2032)
7.3 North America HIV Vaccine Market Size by Country
7.3.1 North America HIV Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America HIV Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe HIV Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe HIV Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe HIV Vaccine Market Size by Country
8.3.1 Europe HIV Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe HIV Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific HIV Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific HIV Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific HIV Vaccine Market Size by Region
9.3.1 Asia-Pacific HIV Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific HIV Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America HIV Vaccine Sales Quantity by Type (2021-2032)
10.2 South America HIV Vaccine Sales Quantity by Application (2021-2032)
10.3 South America HIV Vaccine Market Size by Country
10.3.1 South America HIV Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America HIV Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa HIV Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa HIV Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa HIV Vaccine Market Size by Country
11.3.1 Middle East & Africa HIV Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa HIV Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 HIV Vaccine Market Drivers
12.2 HIV Vaccine Market Restraints
12.3 HIV Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of HIV Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of HIV Vaccine
13.3 HIV Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 HIV Vaccine Typical Distributors
14.3 HIV Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global HIV Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Viral Vector Vaccines
1.3.3 Recombinant Protein Vaccines
1.3.4 Nucleic Acid Vaccines (including mRNA Vaccines)
1.3.5 Other Vaccines
1.4 Market Analysis by Application
1.4.1 Overview: Global HIV Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Preventive Vaccine
1.4.3 Therapeutic Vaccine
1.5 Global HIV Vaccine Market Size & Forecast
1.5.1 Global HIV Vaccine Consumption Value (2021 & 2025 & 2032)
1.5.2 Global HIV Vaccine Sales Quantity (2021-2032)
1.5.3 Global HIV Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Johnson and Johnson (Janssen)
2.1.1 Johnson and Johnson (Janssen) Details
2.1.2 Johnson and Johnson (Janssen) Major Business
2.1.3 Johnson and Johnson (Janssen) HIV Vaccine Product and Services
2.1.4 Johnson and Johnson (Janssen) HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Johnson and Johnson (Janssen) Recent Developments/Updates
2.2 Sanofi-Pasteur
2.2.1 Sanofi-Pasteur Details
2.2.2 Sanofi-Pasteur Major Business
2.2.3 Sanofi-Pasteur HIV Vaccine Product and Services
2.2.4 Sanofi-Pasteur HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Sanofi-Pasteur Recent Developments/Updates
2.3 Uvax Bio
2.3.1 Uvax Bio Details
2.3.2 Uvax Bio Major Business
2.3.3 Uvax Bio HIV Vaccine Product and Services
2.3.4 Uvax Bio HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Uvax Bio Recent Developments/Updates
2.4 AELIX Therapeutics
2.4.1 AELIX Therapeutics Details
2.4.2 AELIX Therapeutics Major Business
2.4.3 AELIX Therapeutics HIV Vaccine Product and Services
2.4.4 AELIX Therapeutics HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AELIX Therapeutics Recent Developments/Updates
2.5 IAVI
2.5.1 IAVI Details
2.5.2 IAVI Major Business
2.5.3 IAVI HIV Vaccine Product and Services
2.5.4 IAVI HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 IAVI Recent Developments/Updates
2.6 HKUMed
2.6.1 HKUMed Details
2.6.2 HKUMed Major Business
2.6.3 HKUMed HIV Vaccine Product and Services
2.6.4 HKUMed HIV Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 HKUMed Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HIV VACCINE BY MANUFACTURER
3.1 Global HIV Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global HIV Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global HIV Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of HIV Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 HIV Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 HIV Vaccine Manufacturer Market Share in 2025
3.5 HIV Vaccine Market: Overall Company Footprint Analysis
3.5.1 HIV Vaccine Market: Region Footprint
3.5.2 HIV Vaccine Market: Company Product Type Footprint
3.5.3 HIV Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global HIV Vaccine Market Size by Region
4.1.1 Global HIV Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global HIV Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global HIV Vaccine Average Price by Region (2021-2032)
4.2 North America HIV Vaccine Consumption Value (2021-2032)
4.3 Europe HIV Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific HIV Vaccine Consumption Value (2021-2032)
4.5 South America HIV Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa HIV Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global HIV Vaccine Sales Quantity by Type (2021-2032)
5.2 Global HIV Vaccine Consumption Value by Type (2021-2032)
5.3 Global HIV Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global HIV Vaccine Sales Quantity by Application (2021-2032)
6.2 Global HIV Vaccine Consumption Value by Application (2021-2032)
6.3 Global HIV Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America HIV Vaccine Sales Quantity by Type (2021-2032)
7.2 North America HIV Vaccine Sales Quantity by Application (2021-2032)
7.3 North America HIV Vaccine Market Size by Country
7.3.1 North America HIV Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America HIV Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe HIV Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe HIV Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe HIV Vaccine Market Size by Country
8.3.1 Europe HIV Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe HIV Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific HIV Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific HIV Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific HIV Vaccine Market Size by Region
9.3.1 Asia-Pacific HIV Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific HIV Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America HIV Vaccine Sales Quantity by Type (2021-2032)
10.2 South America HIV Vaccine Sales Quantity by Application (2021-2032)
10.3 South America HIV Vaccine Market Size by Country
10.3.1 South America HIV Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America HIV Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa HIV Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa HIV Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa HIV Vaccine Market Size by Country
11.3.1 Middle East & Africa HIV Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa HIV Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 HIV Vaccine Market Drivers
12.2 HIV Vaccine Market Restraints
12.3 HIV Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of HIV Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of HIV Vaccine
13.3 HIV Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 HIV Vaccine Typical Distributors
14.3 HIV Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF FIGURES
Table 1. Global HIV Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global HIV Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Johnson and Johnson (Janssen) Basic Information, Manufacturing Base and Competitors
Table 4. Johnson and Johnson (Janssen) Major Business
Table 5. Johnson and Johnson (Janssen) HIV Vaccine Product and Services
Table 6. Johnson and Johnson (Janssen) HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Johnson and Johnson (Janssen) Recent Developments/Updates
Table 8. Sanofi-Pasteur Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi-Pasteur Major Business
Table 10. Sanofi-Pasteur HIV Vaccine Product and Services
Table 11. Sanofi-Pasteur HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Sanofi-Pasteur Recent Developments/Updates
Table 13. Uvax Bio Basic Information, Manufacturing Base and Competitors
Table 14. Uvax Bio Major Business
Table 15. Uvax Bio HIV Vaccine Product and Services
Table 16. Uvax Bio HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Uvax Bio Recent Developments/Updates
Table 18. AELIX Therapeutics Basic Information, Manufacturing Base and Competitors
Table 19. AELIX Therapeutics Major Business
Table 20. AELIX Therapeutics HIV Vaccine Product and Services
Table 21. AELIX Therapeutics HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. AELIX Therapeutics Recent Developments/Updates
Table 23. IAVI Basic Information, Manufacturing Base and Competitors
Table 24. IAVI Major Business
Table 25. IAVI HIV Vaccine Product and Services
Table 26. IAVI HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. IAVI Recent Developments/Updates
Table 28. HKUMed Basic Information, Manufacturing Base and Competitors
Table 29. HKUMed Major Business
Table 30. HKUMed HIV Vaccine Product and Services
Table 31. HKUMed HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. HKUMed Recent Developments/Updates
Table 33. Global HIV Vaccine Sales Quantity by Manufacturer (2021-2026) & (Million Person)
Table 34. Global HIV Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 35. Global HIV Vaccine Average Price by Manufacturer (2021-2026) & (US$/Person)
Table 36. Market Position of Manufacturers in HIV Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 37. Head Office and HIV Vaccine Production Site of Key Manufacturer
Table 38. HIV Vaccine Market: Company Product Type Footprint
Table 39. HIV Vaccine Market: Company Product Application Footprint
Table 40. HIV Vaccine New Market Entrants and Barriers to Market Entry
Table 41. HIV Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global HIV Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 43. Global HIV Vaccine Sales Quantity by Region (2021-2026) & (Million Person)
Table 44. Global HIV Vaccine Sales Quantity by Region (2027-2032) & (Million Person)
Table 45. Global HIV Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 46. Global HIV Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 47. Global HIV Vaccine Average Price by Region (2021-2026) & (US$/Person)
Table 48. Global HIV Vaccine Average Price by Region (2027-2032) & (US$/Person)
Table 49. Global HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 50. Global HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 51. Global HIV Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 52. Global HIV Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 53. Global HIV Vaccine Average Price by Type (2021-2026) & (US$/Person)
Table 54. Global HIV Vaccine Average Price by Type (2027-2032) & (US$/Person)
Table 55. Global HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 56. Global HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 57. Global HIV Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 58. Global HIV Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 59. Global HIV Vaccine Average Price by Application (2021-2026) & (US$/Person)
Table 60. Global HIV Vaccine Average Price by Application (2027-2032) & (US$/Person)
Table 61. North America HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 62. North America HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 63. North America HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 64. North America HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 65. North America HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 66. North America HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 67. North America HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 68. North America HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 69. Europe HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 70. Europe HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 71. Europe HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 72. Europe HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 73. Europe HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 74. Europe HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 75. Europe HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 76. Europe HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 77. Asia-Pacific HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 78. Asia-Pacific HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 79. Asia-Pacific HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 80. Asia-Pacific HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 81. Asia-Pacific HIV Vaccine Sales Quantity by Region (2021-2026) & (Million Person)
Table 82. Asia-Pacific HIV Vaccine Sales Quantity by Region (2027-2032) & (Million Person)
Table 83. Asia-Pacific HIV Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 84. Asia-Pacific HIV Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 85. South America HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 86. South America HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 87. South America HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 88. South America HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 89. South America HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 90. South America HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 91. South America HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 92. South America HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 93. Middle East & Africa HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 94. Middle East & Africa HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 95. Middle East & Africa HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 96. Middle East & Africa HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 97. Middle East & Africa HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 98. Middle East & Africa HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 99. Middle East & Africa HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 100. Middle East & Africa HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 101. HIV Vaccine Raw Material
Table 102. Key Manufacturers of HIV Vaccine Raw Materials
Table 103. HIV Vaccine Typical Distributors
Table 104. HIV Vaccine Typical Customers
LIST OF FIGURES
Figure 1. HIV Vaccine Picture
Figure 2. Global HIV Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global HIV Vaccine Revenue Market Share by Type in 2025
Figure 4. Viral Vector Vaccines Examples
Figure 5. Recombinant Protein Vaccines Examples
Figure 6. Nucleic Acid Vaccines (including mRNA Vaccines) Examples
Figure 7. Other Vaccines Examples
Figure 8. Global HIV Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 9. Global HIV Vaccine Revenue Market Share by Application in 2025
Figure 10. Preventive Vaccine Examples
Figure 11. Therapeutic Vaccine Examples
Figure 12. Global HIV Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global HIV Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global HIV Vaccine Sales Quantity (2021-2032) & (Million Person)
Figure 15. Global HIV Vaccine Price (2021-2032) & (US$/Person)
Figure 16. Global HIV Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 17. Global HIV Vaccine Revenue Market Share by Manufacturer in 2025
Figure 18. Producer Shipments of HIV Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 19. Top 3 HIV Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 20. Top 6 HIV Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 21. Global HIV Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 22. Global HIV Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 23. North America HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 24. Europe HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 25. Asia-Pacific HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 26. South America HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 27. Middle East & Africa HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 28. Global HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 29. Global HIV Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 30. Global HIV Vaccine Average Price by Type (2021-2032) & (US$/Person)
Figure 31. Global HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 32. Global HIV Vaccine Revenue Market Share by Application (2021-2032)
Figure 33. Global HIV Vaccine Average Price by Application (2021-2032) & (US$/Person)
Figure 34. North America HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 35. North America HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 36. North America HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 37. North America HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 38. United States HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Canada HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 40. Mexico HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 41. Europe HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 42. Europe HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Europe HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 44. Europe HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 45. Germany HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 46. France HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 47. United Kingdom HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 48. Russia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 49. Italy HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Asia-Pacific HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 51. Asia-Pacific HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 52. Asia-Pacific HIV Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 53. Asia-Pacific HIV Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 54. China HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 55. Japan HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 56. South Korea HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. India HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. Southeast Asia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Australia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. South America HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 61. South America HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 62. South America HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 63. South America HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 64. Brazil HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 65. Argentina HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Middle East & Africa HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 67. Middle East & Africa HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 68. Middle East & Africa HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 69. Middle East & Africa HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 70. Turkey HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. Egypt HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 72. Saudi Arabia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 73. South Africa HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 74. HIV Vaccine Market Drivers
Figure 75. HIV Vaccine Market Restraints
Figure 76. HIV Vaccine Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of HIV Vaccine in 2025
Figure 79. Manufacturing Process Analysis of HIV Vaccine
Figure 80. HIV Vaccine Industrial Chain
Figure 81. Sales Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Table 1. Global HIV Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global HIV Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Johnson and Johnson (Janssen) Basic Information, Manufacturing Base and Competitors
Table 4. Johnson and Johnson (Janssen) Major Business
Table 5. Johnson and Johnson (Janssen) HIV Vaccine Product and Services
Table 6. Johnson and Johnson (Janssen) HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Johnson and Johnson (Janssen) Recent Developments/Updates
Table 8. Sanofi-Pasteur Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi-Pasteur Major Business
Table 10. Sanofi-Pasteur HIV Vaccine Product and Services
Table 11. Sanofi-Pasteur HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Sanofi-Pasteur Recent Developments/Updates
Table 13. Uvax Bio Basic Information, Manufacturing Base and Competitors
Table 14. Uvax Bio Major Business
Table 15. Uvax Bio HIV Vaccine Product and Services
Table 16. Uvax Bio HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Uvax Bio Recent Developments/Updates
Table 18. AELIX Therapeutics Basic Information, Manufacturing Base and Competitors
Table 19. AELIX Therapeutics Major Business
Table 20. AELIX Therapeutics HIV Vaccine Product and Services
Table 21. AELIX Therapeutics HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. AELIX Therapeutics Recent Developments/Updates
Table 23. IAVI Basic Information, Manufacturing Base and Competitors
Table 24. IAVI Major Business
Table 25. IAVI HIV Vaccine Product and Services
Table 26. IAVI HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. IAVI Recent Developments/Updates
Table 28. HKUMed Basic Information, Manufacturing Base and Competitors
Table 29. HKUMed Major Business
Table 30. HKUMed HIV Vaccine Product and Services
Table 31. HKUMed HIV Vaccine Sales Quantity (Million Person), Average Price (US$/Person), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. HKUMed Recent Developments/Updates
Table 33. Global HIV Vaccine Sales Quantity by Manufacturer (2021-2026) & (Million Person)
Table 34. Global HIV Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 35. Global HIV Vaccine Average Price by Manufacturer (2021-2026) & (US$/Person)
Table 36. Market Position of Manufacturers in HIV Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 37. Head Office and HIV Vaccine Production Site of Key Manufacturer
Table 38. HIV Vaccine Market: Company Product Type Footprint
Table 39. HIV Vaccine Market: Company Product Application Footprint
Table 40. HIV Vaccine New Market Entrants and Barriers to Market Entry
Table 41. HIV Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global HIV Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 43. Global HIV Vaccine Sales Quantity by Region (2021-2026) & (Million Person)
Table 44. Global HIV Vaccine Sales Quantity by Region (2027-2032) & (Million Person)
Table 45. Global HIV Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 46. Global HIV Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 47. Global HIV Vaccine Average Price by Region (2021-2026) & (US$/Person)
Table 48. Global HIV Vaccine Average Price by Region (2027-2032) & (US$/Person)
Table 49. Global HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 50. Global HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 51. Global HIV Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 52. Global HIV Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 53. Global HIV Vaccine Average Price by Type (2021-2026) & (US$/Person)
Table 54. Global HIV Vaccine Average Price by Type (2027-2032) & (US$/Person)
Table 55. Global HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 56. Global HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 57. Global HIV Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 58. Global HIV Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 59. Global HIV Vaccine Average Price by Application (2021-2026) & (US$/Person)
Table 60. Global HIV Vaccine Average Price by Application (2027-2032) & (US$/Person)
Table 61. North America HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 62. North America HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 63. North America HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 64. North America HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 65. North America HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 66. North America HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 67. North America HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 68. North America HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 69. Europe HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 70. Europe HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 71. Europe HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 72. Europe HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 73. Europe HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 74. Europe HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 75. Europe HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 76. Europe HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 77. Asia-Pacific HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 78. Asia-Pacific HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 79. Asia-Pacific HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 80. Asia-Pacific HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 81. Asia-Pacific HIV Vaccine Sales Quantity by Region (2021-2026) & (Million Person)
Table 82. Asia-Pacific HIV Vaccine Sales Quantity by Region (2027-2032) & (Million Person)
Table 83. Asia-Pacific HIV Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 84. Asia-Pacific HIV Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 85. South America HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 86. South America HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 87. South America HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 88. South America HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 89. South America HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 90. South America HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 91. South America HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 92. South America HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 93. Middle East & Africa HIV Vaccine Sales Quantity by Type (2021-2026) & (Million Person)
Table 94. Middle East & Africa HIV Vaccine Sales Quantity by Type (2027-2032) & (Million Person)
Table 95. Middle East & Africa HIV Vaccine Sales Quantity by Application (2021-2026) & (Million Person)
Table 96. Middle East & Africa HIV Vaccine Sales Quantity by Application (2027-2032) & (Million Person)
Table 97. Middle East & Africa HIV Vaccine Sales Quantity by Country (2021-2026) & (Million Person)
Table 98. Middle East & Africa HIV Vaccine Sales Quantity by Country (2027-2032) & (Million Person)
Table 99. Middle East & Africa HIV Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 100. Middle East & Africa HIV Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 101. HIV Vaccine Raw Material
Table 102. Key Manufacturers of HIV Vaccine Raw Materials
Table 103. HIV Vaccine Typical Distributors
Table 104. HIV Vaccine Typical Customers
LIST OF FIGURES
Figure 1. HIV Vaccine Picture
Figure 2. Global HIV Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global HIV Vaccine Revenue Market Share by Type in 2025
Figure 4. Viral Vector Vaccines Examples
Figure 5. Recombinant Protein Vaccines Examples
Figure 6. Nucleic Acid Vaccines (including mRNA Vaccines) Examples
Figure 7. Other Vaccines Examples
Figure 8. Global HIV Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 9. Global HIV Vaccine Revenue Market Share by Application in 2025
Figure 10. Preventive Vaccine Examples
Figure 11. Therapeutic Vaccine Examples
Figure 12. Global HIV Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global HIV Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global HIV Vaccine Sales Quantity (2021-2032) & (Million Person)
Figure 15. Global HIV Vaccine Price (2021-2032) & (US$/Person)
Figure 16. Global HIV Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 17. Global HIV Vaccine Revenue Market Share by Manufacturer in 2025
Figure 18. Producer Shipments of HIV Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 19. Top 3 HIV Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 20. Top 6 HIV Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 21. Global HIV Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 22. Global HIV Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 23. North America HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 24. Europe HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 25. Asia-Pacific HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 26. South America HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 27. Middle East & Africa HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 28. Global HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 29. Global HIV Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 30. Global HIV Vaccine Average Price by Type (2021-2032) & (US$/Person)
Figure 31. Global HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 32. Global HIV Vaccine Revenue Market Share by Application (2021-2032)
Figure 33. Global HIV Vaccine Average Price by Application (2021-2032) & (US$/Person)
Figure 34. North America HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 35. North America HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 36. North America HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 37. North America HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 38. United States HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Canada HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 40. Mexico HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 41. Europe HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 42. Europe HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Europe HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 44. Europe HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 45. Germany HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 46. France HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 47. United Kingdom HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 48. Russia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 49. Italy HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Asia-Pacific HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 51. Asia-Pacific HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 52. Asia-Pacific HIV Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 53. Asia-Pacific HIV Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 54. China HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 55. Japan HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 56. South Korea HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. India HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. Southeast Asia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Australia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. South America HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 61. South America HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 62. South America HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 63. South America HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 64. Brazil HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 65. Argentina HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Middle East & Africa HIV Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 67. Middle East & Africa HIV Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 68. Middle East & Africa HIV Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 69. Middle East & Africa HIV Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 70. Turkey HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. Egypt HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 72. Saudi Arabia HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 73. South Africa HIV Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 74. HIV Vaccine Market Drivers
Figure 75. HIV Vaccine Market Restraints
Figure 76. HIV Vaccine Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of HIV Vaccine in 2025
Figure 79. Manufacturing Process Analysis of HIV Vaccine
Figure 80. HIV Vaccine Industrial Chain
Figure 81. Sales Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
